Tranexamic acid (TA) used in a variety of conditions associated with bleeding has been associated with potential thrombotic side effects such as formation of thrombi and pulmonary embolism (PE). We describe a case of a woman with chronic hemoptysis and a history of PE, who recently used TA as a prophylactic measure, which could have resulted in a new episode of PE. Tranexamic acid probably played a contributory role in the development of her second PE.
Mannucci PMHemostatic drugs. N Engl J Med.1998;339(4): 245-253.
2.
Taparia M., Cordingley FT, Leahy MFPulmonary embolism associated with tranexamic acid in severe acquired haemophilia . Eur J Haematol. 2002;68(5):307-309.
3.
Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev.2007;17(4): CD001886; review.
4.
Woo KS, Tse LK, Woo JL, Vallance-Owen J.Massive pulmonary thromboembolism after antifibrinolytic therapy. Ann Emerg Med. 1989;18(1):116-117.
5.
Sundström A., Seaman H., Kieler H., Alfredsson L.The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG.2009;116(1):91-7.
